Serum albumin binding proteins containing immunoglobulin single variable domains

US11192938B2 · kind B2 · utility

Assignee

• Ablynx N.V. · BE

Inventors

• Judith Baumeister · Wuppertal, DE
• Marie-Paule Lucienne Armanda Bouche · Gentbrugge, BE
• Carlo Boutton · Wielsbeke, BE
• Marie-Ange Buyse · Merelbeke, BE
• Veerle Snoeck · Zingem, BE
• Stephanie Staelens · Wevelgem, BE
• Bruno Dombrecht · Heusden, BE
• Peter Schotte · Zevergem, BE
• Cedric Jozef Neotere Ververken · Merelbeke, BE
• Gerald Beste · Evergem, BE
• Guy Hermans · Merelbeke, BE
• Soren Steffensen · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, BE
• Alexander Szyroki · Goldenstedt, DE
• Tinneke Denayer · Zevergem, BE

Key dates

• Filing date: Jun 6, 2017
• Grant date: Dec 7, 2021
• Expiry date: Jun 6, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/6857
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference and/or give rise to an (aspecific) signal in such an assay (such as in an ADA immunoassay; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.